Story perspectives

Oregon's Drug Board Appoints Young Amid Price Cap Controversy

10/15/2025

31 4

Summary

Story summary

Sarah Young has been appointed executive director of Oregon's Prescription Drug Affordability Board, overseeing the drug price transparency program.
The board faces pressure from drugmakers and allies who oppose price caps and have threatened litigation.
Colorado established a price cap on Enbrel, prompting scrutiny of Oregon's approach.
Ralph Magrish, the board's predecessor, advocated price cap legislation but drew mixed opinions.
The board's next meeting is scheduled for October 15.

1 of 1

Story summary

Sarah Young has been appointed executive director of Oregon's Prescription Drug Affordability Board, overseeing the drug price transparency program.
The board faces pressure from drugmakers and allies who oppose price caps and have threatened litigation.
Colorado established a price cap on Enbrel, prompting scrutiny of Oregon's approach.
Ralph Magrish, the board's predecessor, advocated price cap legislation but drew mixed opinions.
The board's next meeting is scheduled for October 15.